Huimin Wang - Sep 8, 2021 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
CVP, Japan & Intercontinental
Signature
Linda J. Park, Attorney-in-Fact
Stock symbol
EW
Transactions as of
Sep 8, 2021
Transactions value $
-$631,771
Form type
4
Date filed
9/8/2021, 09:04 PM
Previous filing
Aug 9, 2021
Next filing
Oct 8, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Options Exercise $138K +6.35K +6.48% $21.76 104K Sep 8, 2021 Direct F1
transaction EW Common Stock Sale -$770K -6.35K -6.08% $121.25 98K Sep 8, 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Employee Stock Option (Right to Acquire) Options Exercise $0 -6.35K -16.67% $0.00 31.8K Sep 8, 2021 Common Stock 6.35K $21.76 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 4, 2021.
F2 This transaction was executed in multiple trades at prices ranging from $120.9900 to $121.6800. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.